Emkay Global Financial's research report on Colgate-Palmolive
We reiterate our REDUCE call on Colgate due to a high base for growth delivery ahead. The company has executed well on oral care and consistently surprised the street with its performance. However, amid a tough demand setting now, we see price power waning which will limit margin delivery ahead and result in muted earnings. Q2 results were a miss – 10% sales growth (3% lower than our estimate) and 4% adj PAT growth (11% lower). We believe business diversification is key for double-digit growth ahead; the company could double down on personal care offerings which, though, could be margin dilutive.
Outlook
After Q2 results and weak management commentary, we cut FY25-27E earnings 5- 8% and lower our target valuation multiple, from 50x to 47x (now at 10% premium to the last 5YF avg P/E). Our new Sep-25E TP is Rs 3,000.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
